Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC.

Haematologica. 2006 Apr;91(4):522-9.

2.

18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.

Terasawa T, Nihashi T, Hotta T, Nagai H.

J Nucl Med. 2008 Jan;49(1):13-21. Epub 2007 Dec 12. Review.

3.

Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer.

van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ, Groen H, Plukker JT.

J Clin Oncol. 2004 Sep 15;22(18):3805-12. Review.

PMID:
15365078
5.

Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.

Chiewvit S, Thephamongkhol K, Ubolnuch K, Pooliam J, Phongsawat N, Chiewvit P.

J Med Assoc Thai. 2014 Jan;97(1):85-94.

PMID:
24701734
7.

FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.

Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):9-16.

8.

Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.

Zhang Q, Tian T, Wang L, Qiu H, Li D.

Biomed Pharmacother. 2016 Dec;84:1331-1336. doi: 10.1016/j.biopha.2016.09.101. Epub 2016 Oct 31.

PMID:
27810790
9.

The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.

Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, Glanville J, McIntosh H, Renehan A, Weller D, Dunlop M.

Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Review.

10.

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.

J Clin Oncol. 2001 Jan 15;19(2):414-9.

PMID:
11208833
11.
12.

Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.

Terasawa T, Dahabreh IJ, Nihashi T.

Oncologist. 2010;15(7):750-9. doi: 10.1634/theoncologist.2010-0054. Epub 2010 Jun 29. Review.

13.

The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.

Qiu L, Chen Y, Wu J.

Hell J Nucl Med. 2013 Sep-Dec;16(3):230-6. doi: 10.1967/s0024499100091. Epub 2013 Oct 2. Review.

PMID:
24137577
14.

18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis.

Wu LM, Chen FY, Jiang XX, Gu HY, Yin Y, Xu JR.

Eur J Radiol. 2012 Feb;81(2):303-11. doi: 10.1016/j.ejrad.2010.11.020. Epub 2010 Dec 9. Review.

PMID:
21145680
15.
16.

18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

Pakos EE, Fotopoulos AD, Ioannidis JP.

J Nucl Med. 2005 Jun;46(6):958-63.

17.

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, Nihashi T, Nagai H.

J Clin Oncol. 2009 Apr 10;27(11):1906-14. doi: 10.1200/JCO.2008.16.0861. Epub 2009 Mar 9. Review.

PMID:
19273713
18.

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, van Dalen EC.

Cochrane Database Syst Rev. 2015 Sep 29;(9):CD009263. doi: 10.1002/14651858.CD009263.pub2. Review.

19.

Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.

Alkhawtani RHM, Noordzij W, Glaudemans AWJM, van Rijn RS, van der Galiƫn HT, Balink H, Nijland M, Adams HJA, Huls G, van Meerten T, Kwee TC.

Nucl Med Commun. 2018 Jun;39(6):572-578. doi: 10.1097/MNM.0000000000000840.

PMID:
29672465
20.

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin's and Non-Hodgkin's Lymphoma at End of Therapy: A Multiparametric Approach.

Metser U, Mohan R, Beckley V, Moshonov H, Hodgson D, Murphy G.

Nucl Med Mol Imaging. 2016 Mar;50(1):46-53. doi: 10.1007/s13139-015-0368-7. Epub 2015 Sep 29.

Supplemental Content

Support Center